Which NOAC is a direct thrombin inhibitor used for atrial fibrillation anticoagulation?

Which NOAC is a direct thrombin inhibitor used for atrial fibrillation anticoagulation?

• A. Dabigatran
• B. Rivaroxaban
• C. Apixaban
• D. Edoxaban

Answer: (A)

The main idea is distinguishing the target in NOACs: direct thrombin inhibitors directly block thrombin (factor IIa), while factor Xa inhibitors stop thrombin production further upstream. Dabigatran is the only drug among the options that directly inhibits thrombin, making it a direct thrombin inhibitor. The other three—rivaroxaban, apixaban, and edoxaban—work by inhibiting factor Xa, which reduces thrombin generation but does not block thrombin activity itself. In nonvalvular atrial fibrillation, dabigatran is used as an oral anticoagulant through its direct action on thrombin, whereas the others function by inhibiting factor Xa.

The main idea is distinguishing the target in NOACs: direct thrombin inhibitors directly block thrombin (factor IIa), while factor Xa inhibitors stop thrombin production further upstream. Dabigatran is the only drug among the options that directly inhibits thrombin, making it a direct thrombin inhibitor. The other three—rivaroxaban, apixaban, and edoxaban—work by inhibiting factor Xa, which reduces thrombin generation but does not block thrombin activity itself. In nonvalvular atrial fibrillation, dabigatran is used as an oral anticoagulant through its direct action on thrombin, whereas the others function by inhibiting factor Xa.